Shields valorisation in clinical practice (Q3988859)

From EU Knowledge Graph
Revision as of 06:19, 15 December 2021 by DG Regio (talk | contribs) (‎Changed an Item: Adding English translations)
Jump to navigation Jump to search
Project Q3988859 in Netherlands
Language Label Description Also known as
English
Shields valorisation in clinical practice
Project Q3988859 in Netherlands

    Statements

    0 references
    3,027,276.08 Euro
    0 references
    7,998,087.398 Euro
    0 references
    37.85 percent
    0 references
    28 November 2019
    0 references
    28 November 2022
    0 references
    Polyganics
    0 references
    0 references

    53°11'50.71"N, 6°31'35.36"E
    0 references
    9727 DL
    0 references
    9704CE
    0 references
    Lekkage van lichaamssappen na lever- en pancreaschirurgie is een klinisch significant probleem; het leidt tot co-morbiditeit en mortaliteit, en tot additionele zorgkosten oplopend tot meer dan €350 miljoen in Europa per jaar. Polyganics BV (‘Polyganics’) is gestart met de ontwikkeling van Shields; een zelfklevende pleister (‘sealant’) die in uitgebreide laboratorium- en dierstudies overtuigend heeft laten zien bestand te zijn tegen de ‘verterende’ werking van gal- en pancreassappen, en daarnaast bloedingen tegengaat. In dit project zullen Polyganics en Syncom BV (‘Syncom’) activiteiten uitvoeren gericht op de validatie van het prototype en de demonstratie van veiligheid en werkzaamheid in een realistische omgeving (studies in de mens). (Dutch)
    0 references
    Leakage of body juices after liver and pancreatic surgery is a clinically significant problem; it leads to co-morbidity and mortality, and additional healthcare costs up to more than EUR 350 million in Europe per year. Polyganics BV (‘Polyganics’) has started the development of Shields; a self-adhesive patch (‘sealant’) that in extensive laboratory and animal studies has shown convincingly to be resistant to the ‘digestive’ action of bile and pancreatic juices, and also prevents bleeding. In this project, Polyganics and Syncom BV (‘Syncom’) will carry out activities aimed at validating the prototype and demonstrating safety and efficacy in a realistic environment (human studies). (English)
    15 December 2021
    0 references

    Identifiers

    OP-2014-2023-Noord-OPSNN0279
    0 references